Unternehmensprofil der M1 Kliniken AG
Unternehmensprofil der M1 Kliniken AG

Unique business model

Company profile

M1 Kliniken AG, based in Berlin, is one of the fastest growing and leading private providers of health services in the beauty sector. With its products and services, the group of companies with more than 350 employees offers a customer-oriented spectrum of aesthetic and surgical treatments throughout Germany. Our experienced and highly specialised team uses high-quality products and state-of-the-art medical technology to perform more than 400,000 minimally invasive and surgical procedures every year to the highest quality standards.

Business model

With the guiding principle "highest quality at the best price", M1 started in 2012 and has established itself as the market leader for beauty medicine in Germany. M1 aims to achieve this leading position in the international beauty segment as well by constantly expanding abroad.

To realize this vision, M1 has developed a unique business model, which is based on specialisation and thus providing the highest quality in medicine. Experts agree on this and for us, top medicine through specialisation is the corporate DNA. M1 Kliniken is the first company to focus on selected treatments within aesthetic and plastic medicine. The results are economies of scale and affordable prices.

More than 100 highly specialized doctors perform more treatments in their field of specialty than regular doctors. This routine increases safety for our clients. Our own training and further education at the M1 Akademie also contributes to this. At the same time, centralised purchasing enables us to use the most modern technical infrastructure and the highest quality products and medicines at attractive prices. With this specialisation, M1 makes top medicine accessible to the general public.

> 350 employees

> 1.000,000 treatments

> 60 specialist centres worldwide

Latest news

| Investor News

The Supervisory Board of M1 Kliniken AG has appointed Ms. Katharina Zimmnau to the Executive Board of M1 Kliniken AG with effect from 10. December 2025.

| Investor News

  • Group revenue: +6.7% to EUR 274.3 million (YTD Q3 2024: EUR 257.2 million)
  • EBITDA: +9% to EUR 28.2 million (YTD Q3 2024: EUR 25.9 million)
  • EBIT: +11% to EUR 24.5 million (YTD Q3 2024: EUR 22.1 million)
  • EBIT margin: 8.9% (YTD Q3 2024: 8.6%)
  • EBT: +10% to EUR 24.4 million (YTD Q3 2024: EUR 22.2 million)
  • Earnings per share: EUR 0.86 (YTD Q3 2024: EUR 0.77)

| Ad-hoc news

M1 Kliniken AG announces that its 85% subsidiary, HAEMATO AG, today signed an agreement for the sale of its wholly owned subsidiary HAEMATO Pharm GmbH to the PHOENIX group, one of Europe’s leading healthcare providers headquartered in Mannheim. The completion of the transaction remains subject to the customary antitrust approvals. The parties have agreed not to disclose the financial details of the transaction.

With this transaction, M1 Kliniken AG is consistently pursuing its strategic course to position itself as a globally leading, vertically integrated pure-play provider in the field of medical aesthetics.

| Investor News

  • Group revenue: +9.4% to EUR 183.5 million (H1 2024: EUR 167.7 million)
  • EBITDA: +21% to EUR 20.5 million (H1 2024: EUR 17.0 million)
  • EBIT: +24% to EUR 18.0 million (H1 2024: EUR 14.5 million)
  • EBIT margin: 9.8% (H1 2024: 8.6%)
  • EBT: +12% to EUR 16.9 million (H1 2024: EUR 15.0 million)
  • Earnings per share: EUR 0.63 (H1 2024: EUR 0.53)